Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,757Revenue $M64.5Net Margin (%)18.6Z-Score1.9
Enterprise Value $M1,785EPS $0.6Operating Margin %30.4F-Score7
P/E(ttm))157Cash Flow Per Share $0.6Pre-tax Margin (%)17.5Higher ROA y-yY
Price/Book66.810-y EBITDA Growth Rate %0Quick Ratio8.1Cash flow > EarningsY
Price/Sales29.85-y EBITDA Growth Rate %0Current Ratio8.1Lower Leverage y-yN
Price/Cash Flow32.1y-y EBITDA Growth Rate %23.5ROA % (ttm)7.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)24.1Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M19.6ROI % (ttm)10.2Gross Margin Increase y-yN

Gurus Latest Trades with LGND

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDJoel Greenblatt 2014-12-31 Reduce-0.26%$42.36 - $57.96
($52.25)
$ 89.7542%Reduce -99.32%3,766
LGNDKen Fisher 2014-12-31 Add0.01%$42.36 - $57.96
($52.23)
$ 89.7542%Add 132.31%81,908
LGNDJoel Greenblatt 2014-09-30 Add0.23%$46.99 - $64.52
($53.04)
$ 89.7541%Add 894.83%552,053
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 89.7527%New holding55,492
LGNDKen Fisher 2014-06-30 Buy $59.74 - $70.19
($65.09)
$ 89.7527%New holding36,908
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 89.7526%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 89.7542%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 89.7550%New holding6,136
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 89.7585%Sold Out0
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 89.7588%New holding10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.06)
$ 89.7587%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.26)
$ 89.7582%New holding26,900
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patel SunilDirector 2015-03-19Sell4,591$74.4215.26view
Berkman Charles SVP, Gen. Counsel & Secretary 2015-03-16Sell11,264$74.5415.08view
Herman Melanie JDirector of Accounting 2015-03-02Sell535$60.6941.34view
Herman Melanie JDirector of Accounting 2015-02-19Sell510$57.8448.31view
DeSilva Nishan MVP, Corporate Development 2015-02-10Sell2,300$56.3452.25view
Berkman Charles SVP, Gen. Counsel & Secretary 2014-12-31Buy126$45.2389.65view
FOEHR MATTHEW WEVP and COO 2014-12-31Buy46$45.2389.65view
Herman Melanie JDirector of Accounting 2014-12-31Buy103$45.2389.65view
KOZARICH JOHN WDirector 2014-10-15Buy2,000$45.6887.78view
FOEHR MATTHEW WEVP and COO 2014-10-10Buy85$44.9191view

Press Releases about LGND :

    Quarterly/Annual Reports about LGND:

    News about LGND:

    Articles On GuruFocus.com
    dick Feb 13 2015 
    Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
    5 Hot Stocks to Consider Now Mar 30 2012 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
    Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
    Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 


    More From Other Websites
    Ligand Pharmaceuticals (LGND) Shares March Higher, Can It Continue? - Tale of the Tape Apr 16 2015
    Biotech Ligand Gets Sweeter Deal From Partner Viking Apr 10 2015
    Apple Inc. (AAPL), Google Inc (GOOG), Ligand Pharmaceuticals Inc. (LGND): Blue Clay Capital’s... Apr 10 2015
    LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Apr 10 2015
    3 Top-Rated Biotechs Could Take Buy Points Soon Mar 31 2015
    Spectrum Pharmaceuticals Presents New Data on EVOMELATM (CE-Melphalan), at the Annual Meeting of the... Mar 30 2015
    Ligand Pharmaceuticals: Biotech's Jack Of All Trades Mar 25 2015
    Spectrum Pharmaceuticals' CE-melphalan Under Review - Analyst Blog Mar 10 2015
    Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled™ (Propylene... Mar 09 2015
    Ligand to Present at the 27th Annual Roth Conference on March 9th Mar 03 2015
    Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 15.5% - Tale of the Tape Mar 03 2015
    Coverage initiated on Ligand Pharma by CRT Capital Mar 03 2015
    Ligand to Present at the 27th Annual Roth Conference on March 9th Mar 03 2015
    LIGAND PHARMACEUTICALS INC Financials Feb 28 2015
    10-K for Ligand Pharmaceuticals, Inc. Feb 25 2015
    LIGAND PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 23 2015
    Glaxo Submits Another Revolade Application in the EU - Analyst Blog Feb 09 2015
    Ligand Pharmaceuticals (LGND) Posts In-Line Q4 Earnings - Tale of the Tape Feb 09 2015
    LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Feb 09 2015
    Ligand meets 4Q profit forecasts Feb 09 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK